Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans (1) they have made, and (2) are already in progress, to expand molecular radiotherapy service capacity.

NHS England commissions treatments that have either been approved via the National Institute for Health and Care Excellence technology appraisal process or NHS England’s clinical commissioning development process. Service provision will normally be reviewed at the point that new treatments are approved through either of these two routes.

Where additional capacity is required to meet demand, this will be put in place. Developers of new medicines can apply to the Early Access to Medicines Scheme, Project Orbis or The Innovative Licensing and Access Pathway to accelerate the time to market for new products.

In relation to molecular radiotherapy, linked to the implementation of the new service specification, NHS England will be undertaking an assessment of service readiness to implement new technologies.